90 related articles for article (PubMed ID: 15177304)
21. Inhibition of voltage-sensitive calcium channels by the A2A adenosine receptor in PC12 cells.
Park TJ; Chung S; Han MK; Kim UH; Kim KT
J Neurochem; 1998 Sep; 71(3):1251-60. PubMed ID: 9721751
[TBL] [Abstract][Full Text] [Related]
22. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes.
Sun WC; Moore JN; Hurley DJ; Vandenplas ML; Linden J; Cao Z; Murray TF
Vet Immunol Immunopathol; 2008 Jan; 121(1-2):91-100. PubMed ID: 17913243
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
24. A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy.
Lange-Sperandio B; Forbes MS; Thornhill B; Okusa MD; Linden J; Chevalier RL
Nephron Exp Nephrol; 2005; 100(3):e113-23. PubMed ID: 15824514
[TBL] [Abstract][Full Text] [Related]
25. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
26. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
27. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function.
Miller AH; Vogt GJ; Pearce BD
Neuropsychopharmacology; 2002 Dec; 27(6):939-48. PubMed ID: 12464451
[TBL] [Abstract][Full Text] [Related]
28. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
[TBL] [Abstract][Full Text] [Related]
29. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
[TBL] [Abstract][Full Text] [Related]
31. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
32. Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine.
Hein TW; Yuan Z; Rosa RH; Kuo L
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2113-9. PubMed ID: 15914631
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
Torphy TJ; Zhou HL; Cieslinski LB
J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
[TBL] [Abstract][Full Text] [Related]
34. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F
Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model.
Sato Y; Hiramatsu Y; Homma S; Sato S; Onizuka M; Sakakibara Y
J Thorac Cardiovasc Surg; 2003 Jan; 125(1):172-7. PubMed ID: 12539001
[TBL] [Abstract][Full Text] [Related]
36. Rolipram inhibits polarization and migration of human T lymphocytes.
Layseca-Espinosa E; Baranda L; Alvarado-Sánchez B; Portales-Pérez D; Portillo-Salazar H; González-Amaro R
J Invest Dermatol; 2003 Jul; 121(1):81-7. PubMed ID: 12839567
[TBL] [Abstract][Full Text] [Related]
37. Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice.
Yamaki K; Alam AH; Hossain MA; Taneda S; Yanagisawa R; Takano H; Yoshino S
Scand J Immunol; 2005 Oct; 62(4):378-84. PubMed ID: 16253125
[TBL] [Abstract][Full Text] [Related]
38. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.
Schmidt DT; Watson N; Dent G; Rühlmann E; Branscheid D; Magnussen H; Rabe KF
Br J Pharmacol; 2000 Dec; 131(8):1607-18. PubMed ID: 11139438
[TBL] [Abstract][Full Text] [Related]
39. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
40. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.
Schudt C; Winder S; Eltze M; Kilian U; Beume R
Agents Actions Suppl; 1991; 34():379-402. PubMed ID: 1665311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
